September 24th, 2021 | 14:10 CEST
BioNTech, Valneva, Defence Therapeutics: New highs for vaccine stocks?
Investors in COVID-19 vaccine manufacturers have had little reason to rejoice in recent weeks. Top dogs Moderna and BioNTech have come back noticeably from their highs. Valneva's stock plummeted on Monday. Only newcomer Defence Therapeutics has held its ground at a high level. But for all of them, the calm could soon be over, and a new high could begin. Because people in other parts of the world are still not vaccinated. In addition, winter is just around the corner in Western countries, which means that Corona rates are rising. In addition, a new study shows the risk of long-COVID - such as memory and concentration deficits - even in children. With this mix, vaccine stocks face an exciting fall.
time to read: 3 minutes
|
Author:
Fabian Lorenz
ISIN:
BIONTECH SE SPON. ADRS 1 | US09075V1026 , VALNEVA SE EO -_15 | FR0004056851 , DEFENCE THERAPEUTICS INC | CA24463V1013
Table of contents:
"[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.
Author
Fabian Lorenz
For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.
Tag cloud
Shares cloud
Defence Therapeutics: Vaccine newcomer with attractive valuation
Recent news shows that Corona will be with us for a long time. It is good news for Defence Therapeutics. The Canadians' goal is to develop universal vaccines. To that end, they have developed their proprietary Accum™ technology. On this, Defence Therapeutics is working on vaccines against cancer and infectious diseases - these include COVID-19. The Company has now published an update on the development status of the second-generation "non-injectable" COVID vaccine, AccuVAC-IN002, for intranasal administration. In doing so, the researchers emphasize that individuals infected with the Delta strain have a viral load in their nasal cavity that is 1260 times higher compared with the original version of the coronavirus. The last point is extremely important, he said, because current vaccination strategies do not provide protection against this airborne transmission of the virus to the mucosal areas that form the initial site of infection. That means vaccinated individuals can still become infected and develop potentially life-threatening symptoms. That is where Defence Therapeutics' vaccine comes in.
"Defence's new AccuVAC-IN002 formulation enables us to elicit both IgA and IgG antibody responses at the systemic level and mucosal sites. This would have the effect of blocking transmission, thus not only stopping the initial infection but also ensuring nearly 100% blockage of viral release (shedding)," explained Mr. Plouffe, CEO of Defence Therapeutics. "In addition, our new AccuVAC-IN002 formulation can be further developed to function as a "universal" vaccine capable of targeting 4 to 8 strains simultaneously, which would provide effective protection against all known variants and future emerging strains," he added. In addition, he said, the current progression of the SARS-COVID virus suggests that it will evolve into a new influenza-like seasonal virus. Accordingly, vaccination would be needed every 6 to 12 months.
Defence Therapeutics is currently valued at "only" around EUR 170 million. This valuation seems attractive, especially given Valneva's EUR 1.3 billion. While Valneva is already further along in development, if Defence Therapeutics' platform strategy is successful, it should produce a whole series of vaccines.
Valneva: Recovered from the shock?
Keyword Valneva. The share seems to have recovered from the shock at the start of the week. On Monday, the UK government's surprise termination of the supply contract for the Company's COVID-19 vaccine, which is currently under development, resulted in a price slide of over 40%. The canceled supply contract for the classic inactivated vaccine was worth USD 1.4 billion. However, investors now seem to have regained their courage. The Valneva share has gained up to 25% in recent trading days. It has thus broken away from the chart-technically important 200-day line to the upside. Analysts also continue to be optimistic. Goldman Sachs recommends the Valneva share with a price target of EUR 14.50 as a buy. The analysts at Kepler Cheuvreux also believe in the Company's success. They name a price target of EUR 24 and also recommend the share as a buy. Whether the share can make sustained gains will depend on the study results.
BioNTech: Consolidation over?
BioNTech shareholders needed patience in recent weeks. The high in August of around EUR 400 is far behind, and the share is consolidating - with partly high fluctuations - around EUR 300. However, the environment is right. Together with its partner Pfizer, the Company is working on the approval of the vaccine for children. According to both companies, test subjects between the ages of five and eleven have tolerated the active ingredient well. The vaccine elicited a stable immune response, they said. In order to speed up the approval process, the results have already been sent to the relevant authorities in the USA and Europe. Approval could therefore be granted in just a few weeks. There is further positive news from the USA. US President Biden has announced that the country will donate 500 million more vaccine doses to poorer countries. The doses will be ordered from BioNTech/Pfizer. That brings the total US donation commitments to 1.1 billion doses.
As summer comes to an end, vaccine stocks could be poised for a new high. Top dog BioNTech is a base investment in the sector. Defence Therapeutics is still a long way from approval but is also not widely unknown and attractively valued. Valneva, which is still valued at EUR 1.3 billion, will rise and fall with the upcoming trial results.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.
The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.
